Fluvastatin treatment is not associated with an increased incidence of cancer
- 10 August 2006
- journal article
- research article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 60 (9) , 1028-1034
Abstract
Concerns regarding a potential link between statin treatment and increased risk of cancer were raised following the increased cancer incidence observed in patients treated with pravastatin in the Cholesterol and Recurrent Events and Pravastatin in Elderly Individuals at Risk of Vascular Disease studies. The aim of the present study was to investigate the risk of cancer associated with fluvastatin treatment in clinical trials. A pooled analysis of all available, randomised, placebo-controlled trials with fluvastatin with a minimum treatment period of 24 weeks was performed. The cancer incidences were compared in 3512 patients receiving fluvastatin, 20-80 mg/day, and 3289 patients receiving placebo. Overall, fewer patients were diagnosed with cancer in the fluvastatin group compared with the placebo group [220/3512 (6.3%) vs. 263/3289 (8.0%) respectively; p = 0.0309]. Cox regression analysis, adjusted for baseline covariates and stratified by study, revealed a hazard ratio for first cancer diagnosis of 0.812 [95% confidence interval (CI) 0.667-0.989; p = 0.037] for fluvastatin compared with placebo. No significant differences were observed in the incidence of cancers by site, with the exception of non-melanoma skin cancer (103 vs. 125 cases in the fluvastatin and placebo groups respectively; p = 0.047). Cox regression analysis showed that there was no association between baseline low-density lipoprotein cholesterol levels and the risk of developing cancer (hazard ratio 0.998, 95% CI 0.995-1.000; p = 0.107). In conclusion, fluvastatin treatment is not associated with an increased risk of cancer compared with placebo in clinical trials, independent of patient age, treatment duration and baseline cholesterol levels.Keywords
This publication has 31 references indexed in Scilit:
- Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly PatientsThe American Journal of Geriatric Cardiology, 2003
- High-risk elderly patients PROSPER from cholesterol-lowering therapyThe Lancet, 2002
- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialThe Lancet, 2002
- Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media ThicknessCirculation, 2001
- Total cholesterol and risk of mortality in the oldest oldThe Lancet, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Serum Cholesterol and Cancer Risk: An Epidemiologic PerspectiveAnnual Review of Nutrition, 1992
- Declining Serum Cholesterol Levels Prior to Diagnosis of Colon CancerJAMA, 1990
- SERUM CHOLESTEROL AND CANCER IN THE NHANES I EPIDEMIOLOGIC FOLLOWUP STUDYThe Lancet, 1987
- DIETARY AND ENDOGENOUS CHOLESTEROL AND HUMAN CANCEREpidemiologic Reviews, 1984